H2020FP7HORIZON
Fundacion Publica Andaluza Progreso y Salud M.P.
- Country
- ESSpain
- Defence projects
- 0
- Projects, all programmes
- 33
- As coordinator
- 16
- EU contribution (CORDIS)
- EUR 9,249,068
- Active
- 2008 to 2025
Projects
33 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| PLATELET DISORDERSGeneration of human experimental models of Bernard-Soulier Syndrome and Glanzmann Disease using cellular reprogramming | H2020 | 2015 | Coordinator | EUR 173,371 |
| EVOLINEMobile elements: shuffling the regulome in development and disease. | H2020 | 2015 | Coordinator | EUR 265,317 |
| ELIXIR-EXCELERATEELIXIR-EXCELERATE: Fast-track ELIXIR implementation and drive early user exploitation across the life-sciences. | H2020 | 2015 | Participant | EUR 27,425 |
| EYE-RISKExploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways | H2020 | 2015 | Participant | EUR 198,608 |
| PRECISESADSMolecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases | FP7 | 2014 | Participant | EUR 1,826,852 |
| MBCTHERANOSTICSPIONDevelopment and in vivo validation of a SPION based Theranostic nanosystem for the treatment of Metastatic Breast Cancer | H2020 | 2014 | Coordinator | EUR 173,371 |
| EPIPLURIRETROEpigenetic control and impact of mammalian retrotransposons in pluripotent genomes | FP7 | 2013 | Coordinator | EUR 1,453,800 |
| SOMATIC_MOSAICISMLINE-1 retrotransposition in human somatic cells | FP7 | 2013 | Coordinator | EUR 168,896 |
| Magnetic_PCRMagnetic-PCR: An ultrasensitive methodology for Breast cancer detection and characterization | FP7 | 2013 | Coordinator | EUR 230,037 |
| L1-DIGEORGESYNDROMERole of LINE-1 retrotransposons in the human disease DiGeorge Syndrome | FP7 | 2012 | Coordinator | EUR 100,000 |
| REWIRERehabilitative Wayout In Responsive home Environments | FP7 | 2011 | Participant | EUR 24,027 |
| LEUKAEMOGENESISDevelopmental Impact of MLL-AF4 Fusion Gene linked to Infant Acute Lymphoblastic Leukaemia on Human Stem Cell Fate | FP7 | 2009 | Coordinator | EUR 219,298 |
| SOMATIC LINE-1LINE-1 ACTIVITY IN SOMATIC STEM CELLS: IMPACT AND GENOMIC MOSAICISM | FP7 | 2008 | Coordinator | EUR 100,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.